Login to Your Account



Clinic Roundup


Friday, February 25, 2011
PolyMedix Inc., of Radnor, Pa., completed a Phase I exposure-escalation study with its synthetic defensin-mimetic antibiotic, PMX-30063. Results showed that PMX-30063 may be safely administered at a high dose for more than five days. The data supported dosing levels that are being studied in a current Phase II efficacy study in Staph infections. The results also showed similar pharmacokinetic profiles of PMX-30063 in male and female subjects.

To continue reading subscribe now to BioWorld Today

Learn More about BioWorld Today

Already a subscriber? Sign In or Buy now to activate your subscription